Salarius Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
May 18 2022 - 4:10PM
Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage
biopharmaceutical company developing potential new medicines for
patients with sarcomas, pediatric cancers, and other solid and
hematological cancers, today announced that David Arthur, CEO of
Salarius Pharmaceuticals, will be virtually presenting at the H.C.
Wainwright Global Investment Conference being held on May 23-26,
2022.
The presentation will provide an overview of recent business and
corporate achievements at Salarius as well as discuss upcoming
milestones with the Company’s lead assets, seclidemstat and
SP-3164.
Details of the presentation are as follows:
Event: H.C. Wainwright Global
Investment ConferenceDate & Time: On demand,
beginning 7.00 a.m. ET, Tuesday May 24, 2022 Webcast
Link: Salarius Pharmaceuticals Company Presentation
A replay of the presentation will be available for 90 days at
the link above or by visiting www.salariuspharma.com. Registered
investors will be able to schedule a one-on-one meeting via the
conference portal.
About Salarius
Pharmaceuticals
Salarius Pharmaceuticals, Inc. is a
clinical-stage biopharmaceutical company developing cancer
therapies for patients in need of new treatment options. Salarius’
product portfolio includes seclidemstat (SP-2577), the company’s
lead clinical candidate, which is being studied as a potential
treatment for pediatric cancers, sarcomas, and other cancers with
limited treatment options, and SP-3164, an oral small molecule
protein degrader. Seclidemstat is currently in a Phase 1/2 clinical
trial for relapsed/refractory Ewing sarcoma and select additional
sarcomas that share a similar biology to Ewing sarcoma, also
referred to as Ewing-related or FET-rearranged sarcomas.
Seclidemstat has received Fast Track Designation, Orphan Drug
Designation, and Rare Pediatric Disease Designation for Ewing
sarcoma from the U.S. Food and Drug Administration. Salarius is
also exploring seclidemstat’s potential in several cancers with
high unmet medical need, with a second Phase 1/2 clinical study in
hematologic cancers, initiated by MD Anderson Cancer Center.
Salarius has received financial support from the National Pediatric
Cancer Foundation to advance the Ewing sarcoma clinical program and
was also a recipient of a Product Development Award from the Cancer
Prevention and Research Institute of Texas (CPRIT). For more
information, please visit salariuspharma.com or follow Salarius on
Twitter and LinkedIn.
ContactTiberend Strategic Advisors, Inc. Daniel
Kontoh-Boateng (Investors)dboateng@tiberend.com
Bill Borden (Media)bborden@tiberend.com
Salarius Pharmaceuticals (NASDAQ:SLRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Salarius Pharmaceuticals (NASDAQ:SLRX)
Historical Stock Chart
From Apr 2023 to Apr 2024